SCHEMBL3601229

SCHEMBL3601229

COC(CNC(=O)c1ccccc1)OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.68
MEN1 O00255 2/20 0.68
ALDH1A1 P00352 3/20 0.59
GAA P10253 3/20 0.59
KDM4E B2RXH2 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
TDP1 Q9NUW8 1/20 0.55
HPGD P15428 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
ITGAV P06756 2/20 0.49
GLA P06280 1/20 0.49
MAPT P10636 1/20 0.49
PRSS1 P07477 1/20 0.49
CTSG P08311 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7603053 0.89 MEN1 (0.56) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL9312206 0.88 KMT2A (0.67) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL6365588 0.86 MAPT (0.59) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL265112 0.85 KMT2A (0.59) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL5503502 0.84 MEN1 (0.57) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL18680060 0.84 SMN1; SMN2 (0.56) KMT2AMEN1GAASMN1; SMN2NPC1
SCHEMBL7596045 0.84 NAAA (0.51) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL1169501 0.83 KMT2A (0.56) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL9229602 0.83 MEN1 (0.68) KMT2AMEN1ALDH1A1GAAKDM4E
SCHEMBL6810401 0.83 ATM (0.63) KMT2AMEN1ALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114306724-B Embolism microsphere capable of slowly releasing medicine and preparation method thereof 上海汇禾医疗科技有限公司 2022-11-11 CN claimed
CN-115671370-B Embolic microsphere capable of slowly releasing medicine and preparation method thereof 上海汇禾医疗科技股份有限公司 2024-05-24 CN disclosed
CN-115671370-A Embolism microsphere capable of slowly releasing medicine and preparation method thereof 上海汇禾医疗科技有限公司 2023-02-03 CN disclosed
CN-114306724-B Embolism microsphere capable of slowly releasing medicine and preparation method thereof 上海汇禾医疗科技有限公司 2022-11-11 CN disclosed
CN-114306724-A Embolism microsphere capable of slowly releasing medicine and preparation method thereof 上海汇禾医疗科技有限公司 2022-04-12 CN disclosed
CN-106459274-B (ethylene, vinyl acetal) copolymer and its purposes for lithographic printing plate precursor 爱克发有限公司 2019-09-13 CN disclosed
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 US disclosed
US-10221269-B2 (Ethylene, vinyl acetal) copolymers and their use in lithographic printing plate precursors AGFA NV (BE) 2019-03-05 US disclosed
US-10221269-B2 (Ethylene, vinyl acetal) copolymers and their use in lithographic printing plate precursors AGFA NV (BE) 2019-03-05 US disclosed
WO-2016057834-A9 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2017-04-13 WO disclosed
WO-2016057834-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2016-04-14 WO disclosed
WO-2015173231-A1 (ETHYLENE, VINYL ACETAL) COPOLYMERS AND THEIR USE IN LITHOGRAPHIC PRINTING PLATE PRECURSORS AGFA GRAPHICS NV (BE) 2015-11-19 WO disclosed
WO-2015173231-A1 (ETHYLENE, VINYL ACETAL) COPOLYMERS AND THEIR USE IN LITHOGRAPHIC PRINTING PLATE PRECURSORS AGFA GRAPHICS NV (BE) 2015-11-19 WO disclosed
EP-2944657-A1 (Ethylene, Vinyl Acetal) Copolymers and Their Use In Lithographic Printing Plate Precursors AGFA GRAPHICS NV (BE) 2015-11-18 EP disclosed
EP-2944657-A1 (Ethylene, Vinyl Acetal) Copolymers and Their Use In Lithographic Printing Plate Precursors AGFA GRAPHICS NV (BE) 2015-11-18 EP disclosed
US-20130101509-A1 IMAGING AND RADIOTHERAPY METHODS GENERAL ELECTRIC COMPANY (US) 2013-04-25 US disclosed
US-20110286922-A1 IMAGING AND RADIOTHERAPY METHODS GENERAL ELECTRIC COMPANY 2011-11-24 US disclosed
US-7704994-B2 Benzazepine derivatives for the treatment of neurological disorders GLAXO GROUP LIMITED (GB) 2010-04-27 US disclosed
US-20070299056-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BAMFORD MARK J 2007-12-27 US disclosed
WO-2001087851-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130101509-A1 IMAGING AND RADIOTHERAPY METHODS ALDH2, ALDH3A1, ALDH1A1 KMT2A 1972/4885MEN1 2884/4885ALDH1A1 3/4885
US-20110286922-A1 IMAGING AND RADIOTHERAPY METHODS ALDH2, ALDH3A1, ALDH1A1 KMT2A 1972/4885MEN1 2884/4885ALDH1A1 3/4885
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES HPSE, GAA, MAN2B1 KMT2A 4081/4885MEN1 2566/4885ALDH1A1 1376/4885
US-20070299056-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS GRIN2C, TPH1, GRIN2B KMT2A 464/4885MEN1 2336/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.